

Approved by:



CERTIFICATE

2025

Teilgemeinschaftspraxis Molekularpathologie Südbayern
Giesinger Bahnhofplatz 2
81539 München
Germany

has successfully completed the proficiency test

IDH1/IDH2 Mutation Analysis in Gliomas (MolPath)

(Trial Period 20.10.2025 - 07.11.2025)

Berlin, February 6, 2026

Prof. Dr. med. Claudia Wickenhauser
Quality in Pathology - QuIP GmbH

Prof. Dr. med. Markus J. Riemenschneider
Neuropathologie Universitätsklinikum Regensburg

Lead panel institute of the proficiency test:

Prof. Dr. med. Markus J. Riemenschneider, Neuropathology, University Hospital Regensburg, Germany

This certificate includes the separate individual evaluation of the test and the corresponding proficiency test report, the evaluation criteria can be found in the proficiency test report under point 3.2.

This proficiency test was organized by:
Qualitätssicherungs-Initiative Pathologie QuIP GmbH /
Reinhardtstr. 1 / 10117 Berlin / office@quip.eu / www.qualityinpathology.com

